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(t = -0.09, p = 0.93). Probable RCTs in these areas now
account for 4% of all RCTs compared to 1.6% in 1956–60.
Advances in mono-factorial disorders such as CF, Haemophilia,
HD, MD and SCA, have tended to remain relatively constant
across 50 years, whilst multi-factorial diseases such as AD and
CD, continue to attract signiﬁcant interest. Obesity has
attracted an ever increasing number of RCTs. CONCLU-
SIONS: Trials of new treatments within the selected diseases
were expected to increase; however, results reported no evi-
dence of increased research (within the selected disorders) fol-
lowing the identiﬁcation of the causative gene(s). A greater
interest appeared to be directed towards diseases with gene-
environment interaction i.e. obesity. Further development of
this analysis may assist identiﬁcation of genetic research invest-
ments which can translate most effectively to improved clinical
practice.
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MATRIX MODEL FOR DETERMINING A DRUG’S HEALTH
ECONOMIC FOCUSTO OPTIMIZE ITS ECONOMICVIABILITY
Hemels M1, Einarson TR2
1Novo Nordisk, Bagsvaerd, Denmark, 2University of Toronto,Toronto,
ON, Canada
Discovering and developing drugs is a risky process that requires
a great deal of both time and money. To gain competitive advan-
tage, companies must establish the health economic viability of
the product and adapt development plans effectively to meet
market access requirements. To present a conceptual model that
optimizes the economic viability of potential new drugs by iden-
tifying useful properties and obtaining clinical, economic, and
quality-of-life data as early as possible in the product develop-
ment cycle. The matrix is formed by two drug characteristics
of primary importance: indication and mechanism of action
(MOA). Four scenarios arise from this matrix: I = New Market
Entry (drugs having both novel MOA and indication),
II = Product Development (new MOAs for existing indications),
III = Market Expansion (existing MOA but new indication), and
IV = Market Penetration (existing MOA and existing indication).
Economic viability incorporates the following six parameters:
efﬁcacy, tolerability/safety, QOL, pricing, effectiveness, and for-
mulation. To optimize a product’s economic viability, sponsors
should evaluate, based on type of scenario and its requirements
for these six parameters, the health economic challenges ahead to
be overcome in order to achieve successful reimbursement. Drugs
in Scenario I fulﬁll an unmet therapeutic need and are therefore
highly desired. Economic viability for these products is high.
Those with novel MOAs are also highly valued, as they could
treat wider ranges of patients or those who fail other regimens.
Compounds in Scenario IV pose the greatest challenges for health
economic viability. The product is considered a ‘me too’ and,
therefore, there is an increased focus on added value relative to
existing products. Using this matrix can identify early the
optimal position of a new drug, the data required, and when the
data should be collected and veriﬁed. Consequently, development
can be made efﬁcient, with reduced waste of resources and funds.
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OBJECTIVE: Studies have shown that increased co-morbidity is
associated with poor pharmacological adherence. We undertook
to determine the feasibility of using the modiﬁed RxRisk-V
co-morbidity index to predict adherence to lipid lowering
therapy (LLT). METHODS: Using RxAmerica data, patients
18 years and with 18 months of continuous health plan
enrollment from 2001–2005 were included in the analysis if they
were ‘new starts’ with any class of LLT, deﬁned as no prior
treatment in the class for six months. Adherence ratios (deﬁned
as proportions of drug-available days during the follow-up
period) were calculated and patients with adherence ratios0.80
were considered adherent to LLT. Using a modiﬁed RxRisk-V,
co-morbid conditions (CCs) were identiﬁed based on one-year of
prescription claims prior to the index LLT prescription. Multi-
variable logistic regression was used to estimate the age- and
sex-adjusted odds for adherence associated with various levels of
disease co-morbidity. RESULTS: A total of 19,458 patients were
identiﬁed as new starts with an LLT class. The mean age of
patients was 55 years (SD 12.1), 48% were females, and 43%
had 3 CCs. Results of the regression analysis showed that
patients with 1–2 CCs were less likely to be adherent (OR: 0.90;
CI: 0.83–0.99) compared to patients with no CCs. Patients with
3 CCs were more likely to be adherent (OR: 1.10; CI: 1.01–
1.18). The OR for adherence was signiﬁcantly decreased for
individuals with anxiety and tension, pain disorders, and tuber-
culosis. The OR was signiﬁcantly increased for patients with
cardiovascular diseases, psychiatric disorders, gastric acid dis-
orders, and others. CONCLUSION: These results show that
the relationship between adherence and degree of co-morbidity
takes a U-shaped distribution; patients with lower levels of
co-morbidity are less adherent compared to patients with no
co-morbidity, and patients with higher levels of co-morbidity are
more adherent.
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OBJECTIVE: The objective of the analysis was to evaluate
impact of adherence to lipid treatment guidelines [National Cho-
lesterol Education Program’s Third Report on Detection, Evalu-
ation, and Treatment of High Blood Cholesterol and Adult
Treatment Panel’s (NCEP-ATP III)] on stroke events in managed
care patients. METHODS: Patients with laboratory values
for low-density lipoprotein-cholesterol (LDL-C), high-density
lipoprotein-cholesterol (HDL-C), & triglycerides (TG) between
January 1, 2003-December 31, 2005 [index date], no lipid
therapy 6-months pre-index date, and minimum 12 months
health plan eligibility pre- and post-index date were analyzed
using a large integrated United States managed care database.
Patients were classiﬁed as appropriately (AM) or inappropriately
managed (IAM) using baseline lipid levels and the ﬁrst post-index
follow-up lipid panel (goal attainment irrespective of therapy),
and risk stratiﬁcation per NCEP-ATP III guidelines. Post-index,
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stroke event incidence between groups was analyzed descrip-
tively and through a multivariate logistic regression analysis after
controlling for differences in baseline clinical and demographic
variables. RESULTS: Among 8176 study patients (3493 AM;
4683 IAM), AM patients were signiﬁcantly older [51.4  9.1
and 50.0  9.6 years, p < 0.01] and comprised of fewer males
(43.2% vs. 56.2%; p < 0.01). AM patients were more likely to be
at lower risk status at index date versus IAM patients (63% vs.
28%; p < 0.01), and had a signiﬁcantly lower Deyo-Charlson
comorbidity score (0.32  0.56 vs. 0.20  0.44; p < 0.01).
During follow-up, fewer AM patients experienced a stroke event
versus IAM patients (0.7% vs. 1.1%; p = 0.03) and thereby were
36% less likely to have a stroke event (OR: 0.64, 95% CI:
0.44–0.93; p < 0.01). CONCLUSION: Adhering to clinical
guideline treatment recommendations was likely to be associated
with subsequent stroke reductions and possible long-term cost
savings in this managed care population.
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OBJECTIVE: Injectable nicardipine is increasingly used in man-
aging neurovascular conditions. To understand its place in
therapy, we conducted an evidenced-based literature review.
METHODS: The English-language literature in OVID and
Cochrane databases was searched using combinations of these
terms: intracerebral hemorrhage (ICH), neurology, neurosurgery,
nicardipine, stroke, subarachnoid hemorrhage (SAH). Two-
hundred and twenty-three abstracts were identiﬁed; after inde-
pendent review by two individuals, four clinical guidelines, two
meta-analyses, and four randomized controlled trials (RCT) were
deemed relevant. RESULTS: In clinical guidelines, based on
expert opinion, nicardipine was recommended to manage
hypertension in 1) ischemic stroke patients eligible for acute
reperfusion therapy (alternatives: labetalol, nitropaste, and nitro-
prusside); and 2) ICH (alternatives: enalapril, esmolol, hydrala-
zine, labetalol, nitroprusside, nitroglycerin). In a meta-analysis,
nicardipine had no effect on death or dependency in patients with
aneurysmal SAH [RR:0.97 (95%CI:0.78–1.20)]; adverse events
were higher versus placebo [hypotension:34% vs. 5%; phlebi-
tis:22% vs. 5%; pulmonary edema + azotemia: 6% vs. 2%]. In
acute traumatic brain injury, nicardipine had no impact on death
and severe disability [RR:0.25 (95%CI:0.05–1.27)]. Nicar-
dipine’s effect on cerebral blood ﬂow was comparable to labe-
talol (+0.19  3.9 ml/100 g/min vs. -1.55  3.2 ml/100 g/min;
p = 0.39) in ICH, while it increased from baseline in SAH
patients (42.1  12.3 ml/100 g/min vs. 47  10.7 ml/100 g/min;
p < 0.05). In a craniotomy RCT, nicardipine was less effective
than labetalol in preventing emergent hypertension (50% vs.
82%; p = 0.05) and was associated with more tachycardia (20%
vs. 0%; p = 0.11), hypotension (15% vs. 0%; p = 0.23) and
higher cost ($23.65  6.62 vs. $5.23  2.0; p < 0.05). Mean
arterial pressure remained depressed 20 minutes post-infusion
compared to nitroprusside, despite lack of
cumulative nicardipine plasma levels [60  2 mmHg vs.
73  4 mmHg; p < 0.05] in spinal surgery patients. CONCLU-
SION: While nicardipine has a role in select neurovascular
indications, recommendations are based on expert opinion.
Moreover, a lack of beneﬁt has been demonstrated in meta-
analyses and RCT in other neurovascular indications, including
aneurysmal SAH and acute traumatic brain injury.
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OBJECTIVE: The current study evaluated the appropriate utili-
zation of ezetimibe add-on therapy to simvastatin and the cost-
consequences based upon the following outcomes: ezetimibe
response, LDL-C goal achievement, and switch to rosuvastatin.
METHODS: This was a retrospective review of VASDHS
medical records to identify patients with active prescriptions for
ezetimibe and simvastatin between January 1, 2004 and August
31, 2007. Base-case response was deﬁned as 10% LDL-C
reduction from baseline at study endpoint. Additional efﬁcacy
parameters included LDL-C goal achievement and switch to
rosuvastatin if LDL-C goal not met. Pre-post analyses for con-
tinuous and binomial data were performed using Wilcoxon-
ranked sum and McNemar’s tests, respectively. Cost analyses
were conducted from the payer perspective, utilizing total direct
costs. Average cost-effectiveness ratios (CER) were calculated
for (1) ezetimibe response, (2) LDL-C goal achievement, and
(3) switch to rosuvastatin. Sensitivity analyses were performed
varying the base-case response deﬁnition. RESULTS: Overall,
121 patients met inclusion. Baseline characteristics were as
follows: male 97.5%; Caucasian 78.5%; CHD 67.8%; diabetes
63.6%; symptomatic CAD 15.7%; PAD 18.2%; AAA 7.4%;
>20% 10-year risk-score 95.9%; LDL-C goal <100 mg/dL
95.9%; LDL-C goal <70 mg/dL 57.9%; and smoker 28.1%.
Pre-post comparisons showed signiﬁcant differences from base-
line LDL-C and cholesterol for both responders (p < 0.001,
p < 0.001) and non-responders (p = 0.028, p = 0.028). Overall,
88.4% of patients responded to ezetimibe, while 36% of non-
responders had their antilipemic regimen modiﬁed. In addition,
53% of patients reached LDL-C goal. Average CERs over a
9-month period using base-case response deﬁnition were:
$1705.64 per ezetimibe response, $2054.26 per LDL-C goal
achieved, and $2997.56 per switch to rosuvastatin. Sensitivity
analyses showed no change in trend for ezetimibe response, but
changes were observed for the latter parameters. CONCLU-
SION: There is beneﬁt in assessing both response rates as well as
LDL-C goal attainment when determining a cost-analysis of
ezetimibe add-on therapy to simvastatin.
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THE IMPACT OF PHARMACISTS’ INTERVENTIONS:
SENSITIVITY ON PATIENT OUTCOMES IN HYPERLIPIDEMIA
MANAGEMENT
Machado M, Bajcar J, Nassor N, Einarson TR
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OBJECTIVE: Hyperlipidemia increases the risk for cardio-
vascular disease and control is pivotal for preventing subsequent
complications. Multidisciplinary interventions, including phar-
macists, are important for improving patients’ outcomes. Our
objective was to quantify the impact of pharmacist interventions
in enhancing patients’ clinical and humanistic outcomes.
METHODS: Two reviewers searched International Pharmaceu-
tical Abstracts, Medline, Embase, The Cochrane Central Register
of Controlled Trials, 3rd Quarter and CINAHL for pharmacist
interventions in hyperlipidemia. Quality was assessed using
Downs-Black scale. Data extracted included patients enrolled,
study characteristics, intervention type and pre- and post-
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